Generation Bio, Vir partner for mAbs against COVID-9

By The Science Advisory Board staff writers

Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes COVID-19.

The collaboration will allow Generation Bio's gene therapy platform, which delivers genetic information to cells without the use of adeno-associated viruses, to be combined with Vir's neutralizing antibodies, the two firms said.

Vir's leading antibody was developed from a patient who recovered from SARS-CoV-1 and could neutralize SARS-CoV-2, according to Generation Bio and Vir.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking